Skip to Content

LBA: Probably the Best in Class for Treatment of Plaque Psoriasis

At this year’s EADV Congress, Dr. Blauvelt, Oregon, USA, presented a Late Breaking Abstract with promising results for a potent and highly selective allosteric TYK2 inhibitor for the treatment of plaque psoriasis. The results show a clinically effective and generally safe oral therapy for treating patients with moderate-to-severe plaque psoriasis.

Andrew Blauvelt

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top